Novo Nordisk withdraws press statement – had misleading marketing

The Danish Maritime and Commercial High Court has ruled that a Novo Nordisk press announcement had misleading marketing.

Photo: Novo Nordisk / PR

Novo Nordisk has withdrawn a press statement on Tresiba, which was issued on Sep. 19, 2019, after the Danish Maritime and Commercial High Court has ruled that it contained misleading marketing, which Novo Nordisk announces on Monday.

Last year's press announcement stated that Novo expected to present improvements in the average blood sugar level and in cases with low blood sugar –  known as hypoglycemia – in the company's insulin product Tresiba, compared with the competing drug Toujeo from French pharmaceutical firm Sanofi.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs